Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (not Assembly Biosciences, Inc.) on May 14, 2012. The filing reports a material event under Item 8.01 regarding clinical trial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Clinical Trial Results: On May 14, 2012, the company announced positive results from its Phase 3 trial of diltiazem (VEN 307) in patients with anal fissures.
- Documentation: A press release detailing these results is attached as Exhibit 99.1 and incorporated by reference.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the announcement of the positive Phase 3 trial results.
Investor Verification Checklist
- Verify the full details of the Phase 3 trial results for diltiazem (VEN 307) in the attached press release (Exhibit 99.1).
- Confirm the regulatory implications of these positive results for future FDA approval.
- Note the discrepancy between the requested company name (Assembly Biosciences) and the actual registrant (Ventrus Biosciences).